NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic small molecule | Studied as a REV-ERB agonist |
| Molecular formula | C20H24ClN3O4S | Reported for the neutral compound |
| Appearance | Off-white to pale yellow solid | Typical research-grade material |
| Solubility | Sparingly soluble in water | Soluble in solvents such as DMSO |
| Common synonyms | SR9009; Stenabolic | Stenabolic is an informal alias |
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
=== Motion preservation and facet arthroplasty === Independent reviews place TOPS within a broader group of posterior motion-preserving technologies developed to address the trade-off between decompression, stability, and retained segmental motion. Unlike lumbar disc replacement, which principally addresses disc pathology, facet arthroplasty is intended to restore stability after decompression in patients whose disease involves the posterior spinal elements, including the facet joints. Reviews identify preservation of motion and the potential to reduce adjacent-segment disease as key proposed advantages, while emphasizing the importance of patient selection and the need for continued long-term data on implant durability, revision, and adjacent-segment outcomes.
Aged mouse tissues exhibit globally increased malonylation, potentially due to elevated expression of acetyl-CoA carboxylase and reduced activity of the deacylase SIRT5, which depends on declining NAD+ levels. These findings suggest a role for histone malonylation in the epigenetic regulation of aging processes. In type 2 diabetes, lysine malonylation is significantly elevated in liver tissue, as shown in obese mouse models such as db/db and ob/ob mice. Many of the affected proteins are involved in glucose and lipid metabolism, and malonylation of glycolytic enzymes has been shown to suppress their activity, leading to reduced glycolytic flux. Six of the ten glycolytic enzymes are malonylated at sites regulated by the demalonylase SIRT5, which counteracts this inhibition and may serve as a therapeutic target, along with other yet unidentified enzymes that regulate malonylation. In osteoarthritis, SIRT5 expression decreases in cartilage during aging while lysine malonylation increases. In mice, the combination of Sirt5 deficiency and high-fat diet–induced obesity exacerbates joint degeneration, accompanied by widespread hypermalonylation of glycolytic enzymes and impaired chondrocyte metabolism. A rare missense mutation in human SIRT5 (F101L) found in familial osteoarthritis further confirms a direct link between hypermalonylation and osteoarthritis. In resting macrophages, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) binds to inflammatory mRNAs such as TNFα and suppresses their translation.
The intracellular KOR signaling axis involves continued Gi/o coupling on late endosomal membranes, sustained suppression of adenylyl cyclase and cAMP production, and prolonged recruitment of ERK pathway components through Gβγ-dependent mechanisms, thereby establishing a biochemical niche for chronic dynorphin signaling distinct from acute plasma membrane responses. This signaling permits differential integration of intracellular second messenger systems and transcriptional responses compared to plasma membrane-restricted coupling.
Sources: en.wikipedia.org
== Plot == Joe Huff is an Alabama cop who has been suspended for excessive violence. After stopping a supermarket robbery, he is summoned by FBI agent Lance Dockery, who takes him to meet with special agent Frank Cunningham. Cunningham blackmails Joe by threatening to turn Joe's three-week suspension into six months without pay. Cunningham wants Joe to go undercover in Mississippi and infiltrate The Brotherhood, a white supremacist biker gang linked to the murders of government officials and suspected of dealing drugs to the mafia. The Brotherhood is led by Chains Cooper. Joe goes undercover as "John Stone". Tasked with killing a Bolivian man as his initiation, Joe enlists the FBI's help to fake the murder and is accepted into the Brotherhood. However, Chains' right-hand man, Ice Hensley, does not trust Joe and tries to expose him, leading to Ice's death in a high-speed motorcycle chase. Joe learns that the Brotherhood's goal is to eliminate Brent "The Whip" Whipperton, a district attorney running for Governor of Mississippi, who has promised to crack down on crime. They plan to use stolen military weapons to storm the Supreme Court at the Mississippi State Capitol, where Trouble Owens, one of their own, is on trial for murder, to assassinate Whipperton and the judges. When Chains' girlfriend, Nancy, accidentally learns about Joe's identity, he offers her immunity if she cooperates with the FBI. Though reluctant at first, Nancy accepts his offer, but they are discovered when the Bolivian man Joe had supposedly killed as an initiation returns.
== Functions == The endoplasmic reticulum serves many general functions, including the folding of protein molecules in sacs called cisternae and the transport of synthesized proteins in vesicles to the Golgi apparatus. Rough endoplasmic reticulum is also involved in protein synthesis. Correct folding of newly made proteins is made possible by several endoplasmic reticulum chaperone proteins, including protein disulfide isomerase (PDI), ERp29, the Hsp70 family member BiP/Grp78, calnexin, calreticulin, and the peptidylprolyl isomerase family. Only properly folded proteins are transported from the rough ER to the Golgi apparatus – unfolded proteins cause an unfolded protein response as a stress response in the ER. Disturbances in redox regulation, calcium regulation, glucose deprivation, and viral infection or the over-expression of proteins can lead to endoplasmic reticulum stress response (ER stress), a state in which the folding of proteins slows, leading to an increase in unfolded proteins. This stress is emerging as a potential cause of damage in hypoxia/ischemia, insulin resistance, and other disorders.
The Greek key motif consists of four adjacent antiparallel strands and their linking loops. It consists of three antiparallel strands connected by hairpins, while the fourth is adjacent to the first and linked to the third by a longer loop. This type of structure forms easily during the protein folding process. It was named after a pattern common to Greek ornamental artwork (see meander). Due to the chirality of their component amino acids, all strands exhibit right-handed twist evident in most higher-order β-sheet structures. In particular, the linking loop between two parallel strands almost always has a right-handed crossover chirality, which is strongly favored by the inherent twist of the sheet. This linking loop frequently contains a helical region, in which case it is called a β-α-β motif. A closely related motif called a β-α-β-α motif forms the basic component of the most commonly observed protein tertiary structure, the TIM barrel.
FASTpp measures the quantity of protein that resists digestion under various conditions. To this end, a thermostable protease is used, which cleaves specifically at exposed hydrophobic residues. The FASTpp assay combines the thermal unfolding, specificity of a thermostable protease for the unfolded fraction with the separation power of SDS-PAGE. Due to this combination, FASTpp can detect changes in the fraction folded over a large physico-chemical range of conditions including temperatures up to 85 °C, pH 6–9, presence or absence of the whole proteome. Applications range from biotechnology to study of point mutations and ligand binding assays. FASTpp has been used to probe: Lysate effect on protein stability Thermal proteome stability Coupled folding and binding Ligand effects on fraction folded & stability Effects of mutations on fraction folded & stability (e.g. point mutation/missense mutations) Kinetic protein stability
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that activates the REV-ERBα and REV-ERBβ nuclear receptors. It is not an approved drug and has no established human therapeutic use. Most published biological data come from cell and rodent studies.
No. SR9009 is frequently mislabeled as a SARM in online discussions, but it does not target androgen receptors. Its known mechanism involves REV-ERB nuclear receptors and circadian-metabolic gene regulation.
Human clinical data are very limited. There is no approved human use, and safety and efficacy in people are not established. Most evidence comes from preclinical models, so effects observed in animals may not apply to humans.
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.